{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:06:37Z","timestamp":1747181197648,"version":"3.40.5"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"26","license":[{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,30]]},"abstract":"<jats:p>Little is known about differences in the therapeutic efficacy of denosumab in subjects with and without rheumatoid arthritis (RA). This study compares the changes in bone mineral density (BMD) between RA patients and controls without RA who had been treated with denosumab for 2 years for postmenopausal osteoporosis. A total of 82 RA patients and 64 controls were enrolled, who were refractory to selective estrogen receptor modulators (SERMs) or bisphosphonates and completed the treatment of denosumab 60\u2009mg for 2 years. The efficacy of denosumab in RA patients and controls was assessed using areal BMD (aBMD) and T-score of the lumbar spine, femur neck, and total hip. A general linear model with repeated measures analysis of variance was used to determine differences in aBMD and T-score between 2 study groups. No significant differences in percent changes in aBMD and T-scores by denosumab treatment for 2 years at the lumbar spine, femur neck, and total hip were evident between RA patients and controls (<jats:italic toggle=\"yes\">P<\/jats:italic> &gt; .05 of all), except T-score of the total hip (<jats:italic toggle=\"yes\">P<\/jats:italic> = .034). Denosumab treatment equally increased aBMD at the lumbar spine and T-scores at the lumbar spine and total hip between RA patients and controls without statistical differences, but RA patients showed less improvement in aBMD at the femur neck (<jats:italic toggle=\"yes\">p<\/jats:italic>\n                           <jats:sub>time*group<\/jats:sub> = 0.032) and T-scores at the femur neck and total hip than controls (<jats:italic toggle=\"yes\">p<\/jats:italic>\n                           <jats:sub>time*group<\/jats:sub> = 0.004 of both). Changes in aBMD and T-scores after denosumab treatment in RA patients were not affected by previous use of bisphosphonates or SERMs. Differences of T-score at the femur neck among previous bisphosphonate users and aBMD and T-score at the femur neck and T-scores at the total hip were evident. This study revealed that 2 years of denosumab treatment in female RA patients achieved comparable efficacy on BMD to controls at the lumbar spine, but showed somewhat insufficient improvement at the femur neck and total hip.<\/jats:p>","DOI":"10.1097\/md.0000000000034219","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T18:06:20Z","timestamp":1688148380000},"page":"e34219","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["The comparable efficacy of denosumab on bone mineral density in rheumatoid arthritis patients with postmenopausal osteoporosis: A retrospective case-control study"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7780-0167","authenticated-orcid":false,"given":"Seong-Kyu","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Won","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwajeong","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Hoon","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Yoon","family":"Choe","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boyoung","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review.","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"680043","DOI":"10.3389\/fphar.2021.680043","article-title":"The therapeutic landscape of rheumatoid arthritis: current state and future directions.","volume":"12","author":"Shams","year":"2021","journal-title":"Front Pharmacol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13075-021-02503-0","article-title":"Bone mineral density and microarchitecture among Chinese patients with rheumatoid arthritis: a cross-sectional study with HRpQCT.","volume":"23","author":"Jin","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.3390\/jcm9103361","article-title":"Bone loss, osteoporosis, and fractures in patients with rheumatoid arthritis: a review.","volume":"9","author":"Fardellone","year":"2020","journal-title":"J Clin Med"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1186\/s12891-021-04403-5","article-title":"Prevalence and risk factors for bone loss in rheumatoid arthritis patients from South China: modeled by three methods.","volume":"22","author":"Hu","year":"2021","journal-title":"BMC Musculoskelet Disord"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.immuni.2017.02.006","article-title":"Immunopathogenesis of rheumatoid arthritis.","volume":"46","author":"Firestein","year":"2017","journal-title":"Immunity"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","article-title":"Osteoporosis.","volume":"393","author":"Compston","year":"2019","journal-title":"Lancet"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3390\/cells8080826","article-title":"WNT signaling in disease.","volume":"8","author":"Ng","year":"2019","journal-title":"Cells"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL.","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"717065","DOI":"10.3389\/fphar.2021.717065","article-title":"Recent progresses in the treatment of osteoporosis.","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S2213-8587(17)30188-2","article-title":"Osteoporosis treatment: recent developments and ongoing challenges.","volume":"5","author":"Khosla","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1359\/jbmr.081112","article-title":"Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine\/human) RANKL.","volume":"24","author":"Kostenuik","year":"2009","journal-title":"J Bone Miner Res"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis.","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1007\/s10067-018-4218-8","article-title":"The association between 10-year fracture risk by FRAX and osteoporotic fractures with disease activity in patients with rheumatoid arthritis.","volume":"37","author":"Phuan-Udom","year":"2018","journal-title":"Clin Rheumatol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"15844","DOI":"10.1038\/s41598-022-20016-x","article-title":"The prevalence of osteoporosis in rheumatoid arthritis patient: a systematic review and meta-analysis.","volume":"12","author":"Moshayedi","year":"2022","journal-title":"Sci Rep"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"799575","DOI":"10.3389\/fimmu.2021.799575","article-title":"The efficacy of denosumab in patients with rheumatoid arthritis: a systematic review and pooled analysis of randomized or matched data.","volume":"12","author":"Hu","year":"2022","journal-title":"Front Immunol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"rkab099","DOI":"10.1093\/rap\/rkab099","article-title":"Therapeutic efficacy of denosumab for rheumatoid arthritis: a systematic review and meta-analysis.","volume":"5","author":"Yagita","year":"2021","journal-title":"Rheumatol Adv Pract"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative.","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(02)08761-5","article-title":"Diagnosis of osteoporosis and assessment of fracture risk.","volume":"359","author":"Kanis","year":"2002","journal-title":"Lancet"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s001980050281","article-title":"An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of scientific advisors, International Osteoporosis Foundation.","volume":"11","author":"Kanis","year":"2000","journal-title":"Osteoporos Int"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician\u2019s guide to prevention and treatment of osteoporosis.","volume":"33","author":"LeBoff","year":"2022","journal-title":"Osteoporos Int"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s001980050093","article-title":"Updated data on proximal femur bone mineral levels of US adults.","volume":"8","author":"Looker","year":"1998","journal-title":"Osteoporos Int"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1359\/jbmr.1997.12.8.1316","article-title":"Standardization of femur BMD.","volume":"12","author":"Hanson","year":"1997","journal-title":"J Bone Miner Res"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/art.1780270902","article-title":"Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint.","volume":"27","author":"Bromley","year":"1984","journal-title":"Arthritis Rheum"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1210\/edrv.20.3.0367","article-title":"Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.","volume":"20","author":"Suda","year":"1999","journal-title":"Endocr Rev"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S8756-3282(99)00121-0","article-title":"A novel molecular mechanism modulating osteoclast differentiation and function.","volume":"25","author":"Yasuda","year":"1999","journal-title":"Bone"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/art.23417","article-title":"Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial.","volume":"58","author":"Cohen","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/annrheumdis-2015-208052","article-title":"Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial.","volume":"75","author":"Takeuchi","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"8740","DOI":"10.3390\/ijms23158740","article-title":"Mechanisms of systemic osteoporosis in rheumatoid arthritis.","volume":"23","author":"Pietschmann","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10067-019-04771-3","article-title":"Effects of 1-year anti-TNF-\u03b1 therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis.","volume":"39","author":"Guly\u00e1s","year":"2020","journal-title":"Clin Rheumatol"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/art.25053","article-title":"Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone.","volume":"62","author":"Garnero","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"R33-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American association of clinical endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update.","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40634-019-0211-7","article-title":"Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates.","volume":"6","author":"Kaneko","year":"2019","journal-title":"J Exp Orthop"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1373\/clinchem.2016.259085","article-title":"Bone turnover markers in the diagnosis and monitoring of metabolic bone disease.","volume":"63","author":"Greenblatt","year":"2017","journal-title":"Clin Chem"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034219","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:07:34Z","timestamp":1746324454000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":35,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000034219","relation":{},"ISSN":["0025-7974"],"issn-type":[{"type":"print","value":"0025-7974"}],"subject":[],"published":{"date-parts":[[2023,6,30]]}}}